Related Experiment Video
Updated: Aug 15, 2026
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome
Colleen Ann Malloy1, Pamela Nicoski, Jonathan K Muraskas
1Division of Neonatology, Department of Pediatrics, Ronald McDonald Children's Hospital at Loyola University Medical Center, Maywood, IL 60153, USA. c-malloy@northwestern.edu
Aim:
To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS).
Methods:
Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO2) requirement in the first 48 h after surfactant therapy.
Results:
58 infants completed the study. The mean gestational ages for the poractant and beractant groups were 29.6+/-3.6 and 29.3+/-2.9 wk, with average birthweights of 1394+/-699 and 1408+/-534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO2 requirement compared to those who received beractant (p=0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the group that received beractant (45%) (p=0.02).
Conclusions:
Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.
